About this Research Topic
Cancer, a heterogeneous disease characterized by cell death disorder, remains one of the leading causes of death worldwide. The past decade has witnessed considerable breakthroughs in cancer immunotherapy, which activates and enhances the immune system's effects on cancer cells. Immunogenic cell death (ICD) is a form of cell death capable of recruiting the immune system. In cancer immunotherapy, ICD plays a critical role in driving autoimmunity and enhancing immune-mediated elimination. Importantly, ICD involves the release of DAMPs from dying cancer cells, leading to the activation of tumor-specific immune responses and the development of immunological memory.
Non-coding RNA (ncRNA) is a type of RNA transcript without protein-coding ability. Regulatory ncRNAs, especially miRNAs, lncRNAs, and circRNAs, can regulate gene expression at the post-transcriptional level, affecting various cellular processes. Even a single ncRNA can modulate hundreds of downstream targets. Given the significant regulatory effects of ncRNAs, it is interesting to explore the role of ICD-related ncRNAs in cancer.
RNAs account for 75% of the human genome, with ncRNAs comprising about 97% of these transcripts. Among them, miRNAs, which function as negative gene regulators by downregulating the expression of target genes, are about 22 nucleotides long. LncRNAs, with lengths over 200 nucleotides, regulate downstream processes at epigenetic and transcriptional levels, performing a variety of molecular functions. CircRNAs, with a covalently closed circular structure, primarily function as “miRNA sponges” to further regulate cellular processes. By elucidating the functions of miRNAs, lncRNAs, and circRNAs in ICD and evaluating their therapeutic potential as targets, this research topic aims to contribute to the advancement of cancer immunology and offer new perspectives for cancer treatment.
Given the high incidence and rising trend of cancer, it is urgent to clarify its deep pathogenesis and develop promising treatments. This Research Topic focuses on investigating the role of ICD-related ncRNAs in cancer. The primary objective is to explore the immunomodulatory properties of ncRNAs on ICD, investigate their underlying mechanisms of action, and develop novel biomarkers and therapeutic approaches.
We welcome researchers to submit original research articles, review articles, mini-reviews, case reports, and meta-analyses, including but not limited to the following subtopics:
- Expression and regulation of ICD-related miRNAs in cancer
- Level and role of ICD-related lncRNAs in cancer
- Expression and modulation of ICD-related circRNAs in cancer
- ncRNAs as key regulators in cancer immunotherapy
- ncRNAs as potential therapeutic targets in cancer
- Regulating ICD as a potential approach in cancer
Non-coding RNA (ncRNA) is a type of RNA transcript without protein-coding ability. Regulatory ncRNAs, especially miRNAs, lncRNAs, and circRNAs, can regulate gene expression at the post-transcriptional level, affecting various cellular processes. Even a single ncRNA can modulate hundreds of downstream targets. Given the significant regulatory effects of ncRNAs, it is interesting to explore the role of ICD-related ncRNAs in cancer.
RNAs account for 75% of the human genome, with ncRNAs comprising about 97% of these transcripts. Among them, miRNAs, which function as negative gene regulators by downregulating the expression of target genes, are about 22 nucleotides long. LncRNAs, with lengths over 200 nucleotides, regulate downstream processes at epigenetic and transcriptional levels, performing a variety of molecular functions. CircRNAs, with a covalently closed circular structure, primarily function as “miRNA sponges” to further regulate cellular processes. By elucidating the functions of miRNAs, lncRNAs, and circRNAs in ICD and evaluating their therapeutic potential as targets, this research topic aims to contribute to the advancement of cancer immunology and offer new perspectives for cancer treatment.
Given the high incidence and rising trend of cancer, it is urgent to clarify its deep pathogenesis and develop promising treatments. This Research Topic focuses on investigating the role of ICD-related ncRNAs in cancer. The primary objective is to explore the immunomodulatory properties of ncRNAs on ICD, investigate their underlying mechanisms of action, and develop novel biomarkers and therapeutic approaches.
We welcome researchers to submit original research articles, review articles, mini-reviews, case reports, and meta-analyses, including but not limited to the following subtopics:
- Expression and regulation of ICD-related miRNAs in cancer
- Level and role of ICD-related lncRNAs in cancer
- Expression and modulation of ICD-related circRNAs in cancer
- ncRNAs as key regulators in cancer immunotherapy
- ncRNAs as potential therapeutic targets in cancer
- Regulating ICD as a potential approach in cancer
Keywords: Immunogenic cell death, miRNA, lncRNA, circRNA, cancer immunotherapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
